Pacific Bio (NASDAQ: PACB) reported Q2 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $39.8 million versus the consensus estimate of $36.66 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.